PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportssquamous cell carcinoma of head and neck
MeSH D000077195 - squamous cell carcinoma of head and neck
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002294:Squamous cell carcinoma
18 Companies
8 Drugs
$
Success rate
D006258:Head and neck neoplasms
56 Companies
8 Drugs
$
Success rate
D000077195: 
Squamous cell carcinoma of head and neck
2 Companies
2 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Bristol Myers SquibbNivolumab Opdivo  2015-06-19 $8,885 M Q2/23-Q1/24 
Merck Sharp & DohmePembrolizumab Keytruda  2015-07-17 $26,163 M Q2/23-Q1/24 
Clinical Trials
Historical Success Rate
Phase 1
71%
94/133
Phase 2
20%
33/168
Phase 3
20%
10/49
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bristol Myers Squibb
Nivolumab,
Transplatin,
Albumin,
Antithrombin iii,
Nogapendekin alfa,
Linrodostat,
Inbakicept,
VARLILUMAB,
Sodium chloride,
CABIRALIZUMAB,
ENADENOTUCIREV,
LIRILUMAB,
MOTOLIMOD
Merck Sharp & Dohme
Pembrolizumab,
Transplatin,
Albumin,
Antithrombin iii,
Aglatimagene besadenovec,
Sodium chloride,
Sodium lactate,
EFTILAGIMOD ALFA,
LADIRATUZUMAB VEDOTIN,
Vibostolimab,
Microcrystalline cellulose,
Ngm707,
Ngm438,
Bca101,
Flt3l,
Xnw5004,
Gb1275
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use